This Phase II trial is evaluating how effective two different combinations of treatments including anticancer drugs, chemotherapy and immunotherapy, are at treating classical Hodgkin lymphoma.
This trial is treating patients with Hodgkin's Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
This is a non-randomised, parallel assignment study that has three parts. Part A involves the anticancer drug Brentuximab vedotin and chemotherapy drugs doxorubicin, vinblastine, and dacarbazine (this combination is also known as A+AVD) being administered separately via intravenous infusion (IV) to participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle. Participants in Part A will also be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Part B involves the anticancer drug Brentuximab vedotin, immunotherapy drug nivolumab, and chemotherapy drugs doxorubicin and dacarbazine (this combination is also known as AN+AD) being administered separately via IV to participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle. Part C involves AN+AD being administered separately via IV in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
Recruiting Hospitals Read More